StockData
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. (ORMP) stock

ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.87−0.03 (-0.77%)

Close on Nov 17, 2026Market cap $160.98MP/E 0.9Yield 6.46%

Oramed Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Oramed Pharmaceuticals's pe ratio was 1.0× on Nov 11, 2026, against 2.9× a year earlier. Over the last 4 years it ranged from 1.0× to 43.2×, with a median of 9.2×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.0×−1.9
2025Dec 31, 20252.9×−24.0
2024Dec 31, 202426.9×+23.2
2020Mar 31, 20203.7×−2.6
2019Dec 31, 20196.3×−2.9
2015Jun 30, 20159.2×+1.8
2014Dec 31, 20147.4×−21.6
2013Dec 31, 201328.9×–

More Oramed Pharmaceuticals figures

See a number that looks wrong?